2.2. Pediatrics

Although treatment durations have not been solidified, experts recommend that dalteparin therapy should be continued for less than or equal to 3 months in pediatric patients with provoked DVT or PE and up to 12 months (range, 6 to 12 months) in pediatric patients with unprovoked DVT or PE15. Dalteparin treatment recommendations for pediatric patients are summarized in Table 4.

Table 4. LMWH Recommended Treatment Duration (Pediatric Patients) 1,2,4,15
Treatment Indication Drug Name Treatment Duration Range Maximum Treatment Duration
Venous thromboembolism treatment Dalteparin 3 to 12 months 12 months